Lipoatrophy & HIV: Treatment

Overview | News | Research

Overview

The Skinny on Body Fat and HIV (Summer 2009)
To read PDF, click here.
In Achieve, from ACRIA and GMHC
Sculptra (Formerly New Fill) for Facial Wasting -- Where to Find Information on the Patient-Assistance Program (December 31, 2004)
In AIDS Treatment News, from AIDS Treatment News
Cheek to Chic: Lipoatrophy Treatments Compared (April 2004)
Brief summaries of three facial wasting treatments: New-Fill (called Sculptra in the United States), SilSkin and Bio-Alcamid.
In POZ
New Facial Filling Treatment for Lipodystrophy (September/October 2001)
How New-Fill works to help facial wasting.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network

News

Filler Boosts Infection Risk in HIV Patients (October 4, 2012)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Facial Lipoatrophy Treatments: Help Us Remove Barriers to Access (April 15, 2011)
"Access to these products has gotten worse, not better, after January of 2010. Now we are asking for your help to sign this petition to be sent to Medicare to have them increase the rates for administering the products to patients."
From TheBody.com
Medicare to Pay for "Fillers" in HIV Patients (March 26, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Soria Announces the Addition of Lipoatrophy Repairing Treatment to the Common Services Portfolio of the National Health System (August 4, 2008)
To read PDF, click here.
From Ministerio de Sanidad Y Consumo
FDA Approves Radiesse for Treating Facial Lipoatrophy (December 29, 2006)
From U.S. Food and Drug Administration
FDA Approves Radiesse Facial Filler for Two New Aesthetic Indications (December 27, 2006)
To read PDF, click here.
From BioForm Medical, Inc.
Health Canada Provides Bio-Alcamid Injections for Facial Wasting; Full Approval Expected Soon (July 29, 2005)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Sculptra Costs Four Times More in U.S. Than in Europe (September 24, 2004)
In Washington Blade
Approval of Sculptra for Treating Facial Lipoatrophy (August 3, 2004)
From U.S. Food and Drug Administration
Lipoatrophy Treatment Nears Approval in U.S. (March 26, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The FDA Has Accepted the Filing for an Injectable Poly-L-Lactic Acid Called "Sculptra" to Treat Facial Lipoatrophy (February 27, 2004)
The facial wasting treatment known outside the United States as New-Fill moves one step closer to U.S. approval.
To read PDF, click here.
In STEP Ezine, from Seattle Treatment Education Project
Aventis Applies for FDA Approval of Lipoatrophy Treatment (February 10, 2004)
The facial wasting treatment known most widely as New-Fill seeks review for possible approval in the United States.
From Advocate.com

MOST VIEWED ARTICLES

	HIV Management Today: Mental Health & HIV, the Uncharted Territory
	10 Top Studies Whose Impact Will Last Well Beyond CROI 2013
	Danish Study Targets HIV Reservoir, in Latest Search for HIV Cure
	CROI 2013: Women's Issues in HIV Research (Video)
	HIV Opportunistic Infection Guidelines Updated
	PrEP Failures and Successes: One Study Whose Impact Will Last Well Beyond CROI 2013

More Most Viewed Articles

TheBodyPRO.com is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. TheBodyPRO.com and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of TheBodyPRO.com's homepage, topic pages, page designs and HTML code. General Disclaimer: TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.